Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic (Q38536296)

3 September 2017

1 reference

title

Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic (English)

1 reference

3 September 2017

0 references

Steven D Burdette

1

1 reference

PubMed ID

26105167

3 September 2017

Robin Trotman

series ordinal

2

1 reference

PubMed ID

26105167

3 September 2017

language of work or name

English

0 references

publication date

23 June 2015

1 reference

Clinical Infectious Diseases

3 September 2017

1 reference

3 September 2017

61

1 reference

3 September 2017

8

1 reference

3 September 2017

1315-1321

1 reference

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

3 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Oxazolidinones: activity, mode of action, and mechanism of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

The oxazolidinones: past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

The chemistry of peptidyltransferase center-targeted antibiotics: enzymatic resistance and approaches to countering resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Tedizolid: a new oxazolidinone antimicrobial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Tedizolid for the management of human infections: in vitro characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

In vitro antimicrobial activity of the novel oxazolidinone tedizolid and comparator agents against Staphylococcus aureus and linezolid-resistant Gram-positive pathogens: a multicentre study in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Resistance to linezolid caused by modifications at its binding site on the ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Tedizolid: a novel oxazolidinone for Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV501

21 January 2018

Identifiers

DOI

10.1093/CID/CIV501

1 reference

3 September 2017

1 reference

PubMed ID

26105167